RT Journal Article
SR Electronic
T1 High levels of SARS-CoV-2 specific T-cells with restricted functionality in patients with severe course of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.08.20148718
DO 10.1101/2020.07.08.20148718
A1 Schub, David
A1 Klemis, Verena
A1 Schneitler, Sophie
A1 Mihm, Janine
A1 Lepper, Philipp M.
A1 Wilkens, Heinrike
A1 Bals, Robert
A1 Eichler, Hermann
A1 Gärtner, Barbara C.
A1 Becker, Sören L.
A1 Sester, Urban
A1 Sester, Martina
A1 Schmidt, Tina
YR 2020
UL http://medrxiv.org/content/early/2020/07/09/2020.07.08.20148718.abstract
AB Patients infected with SARS-CoV-2 differ in the severity of disease. In this study, SARS-CoV-2 specific T-cells and antibodies were characterized in patients with different COVID-19 related disease severity. Despite severe lymphopenia affecting all major lymphocyte subpopulations, patients with severe disease mounted significantly higher levels of SARS-CoV-2 specific T-cells as compared to convalescent individuals. SARS-CoV-2 specific CD4 T-cells dominated over CD8 T-cells and closely correlated with the number of plasmablasts and SARS-CoV-2 specific IgA- and IgG-levels. Unlike in convalescents, SARS-CoV-2 specific T-cells in patients with severe disease showed marked alterations in phenotypical and functional properties, which also extended to CD4 and CD8 T-cells in general. Given the strong induction of specific immunity to control viral replication in patients with severe disease, the functionally altered phenotype may result from the need for contraction of specific and general immunity to counteract excessive immunopathology in the lung.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by institutional funds, and in part by grants of Saarland University, the State of Saarland, and the Dr. Rolf M. Schwiete Stiftung to R.B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Aerztekammer des Saarlandes (reference numbers 76/20; l62/20)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.